Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 14,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Surgical Bleeding
Interventions: HEMOBLAST™ Bellows, absorbable gelatin sponge with thrombin; Device
Lead sponsor: Dilon Technologies Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Carmel, Indiana • Baltimore, Maryland + 2 more

Conditions: Allergic Conjunctivitis
Interventions: REGN5713, REGN5715, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Andover, Massachusetts • Lincoln, Nebraska

Conditions: Generalized Myasthenia Gravis
Interventions: Ravulizumab, Placebo; Biological · Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Irvine, California • Loma Linda, California + 43 more

Conditions: Polymyalgia Rheumatica
Interventions: Sarilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 47
States / cities: Avondale, Arizona • Phoenix, Arizona • Tucson, Arizona + 42 more

Conditions: Ischemic Cardiomyopathy
Interventions: myoblast, sham; Biological
Lead sponsor: Mytogen, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Gilbert, Arizona

Conditions: Obesity
Interventions: BMF-650; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Actinic Keratosis
Interventions: Imiquimod, Zyclara®, Vehicle Cream; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 27
States / cities: Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more

Conditions: Multiple Sclerosis (MS)
Interventions: Nabiximols, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Port Charlotte, Florida • Tampa, Florida + 11 more

Conditions: Virus Diseases
Interventions: GSK1325756 (Danirixin), Placebo To Match GSK1325756, Oseltamivir Phosphate, Placebo To Match Oseltamivir Phosphate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Palmetto Bay, Florida • Blackfoot, Idaho • Oklahoma City, Oklahoma + 2 more

Conditions: Actinic Keratosis (AK)
Interventions: Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily, Placebo twice daily; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Cerritos, California • Fremont, California • Palm Springs, California + 14 more

Conditions: Parkinson's Disease
Interventions: piclozotan, 0.9% sodium chloride (normal saline); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Fountain Valley, California • Tampa, Florida • Atlanta, Georgia + 2 more

Conditions: Geographic Atrophy
Interventions: Tinlarebant, Placebo; Drug
Lead sponsor: Belite Bio, Inc; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 22
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 19 more

Conditions: Molluscum Contagiosum
Interventions: SB206 12%, Placebo; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 35
States / cities: Mobile, Alabama • Glendale, Arizona • Little Rock, Arkansas + 32 more

Conditions: Covid19
Interventions: Aviptadil, Aviptadil Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: SPD489 (Lisdexamfetamine dimesylate), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 55
States / cities: Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 51 more

Conditions: Chronic Migraine
Interventions: cyclobenzaprine hydrochloride, placebo; Drug
Lead sponsor: Kennedy Medical Group; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cherry Hill, New Jersey

Conditions: Herpes Labialis
Interventions: iontophoretic acyclovir; Device
Lead sponsor: Transport Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 26
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more

Conditions: Hair Thinning
Interventions: Nutrafol Supplement capsules, Placebo capsules; Dietary Supplement · Other
Lead sponsor: Ablon Skin Institute Research Center; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine, Duloxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 56
States / cities: Beverly Hills, California • Chino, California • Garden Grove, California + 53 more

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions: CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules; Drug · Other
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: Atrial Fibrillation
Interventions: MAA868 Cohort 1, MAA868 Cohort 2, MAA868 Cohort 3, Placebo; Biological · Other
Lead sponsor: Anthos Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Beverly Hills, California • Wichita, Kansas • Alexandria, Louisiana + 3 more

Conditions: Healthy Volunteer
Interventions: Placebo, RO5024048; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Glendale, California • Eatontown, New Jersey

Conditions: Low Back Pain
Interventions: Buprenorphine, Placebo; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years and older
Enrollment: 752 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 60
States / cities: Mobile, Alabama • Phoenix, Arizona • Anaheim, California + 51 more

Conditions: Ovarian Cancer
Interventions: MORAb-003 (farletuzumab), 0.9% Saline, Paclitaxel; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 34
States / cities: Mobile, Alabama • Phoenix, Arizona • Greenbrae, California + 29 more

Search by objective public record fields.

Evaluation of Safety of HEMOBLAST Bellows in Spine Surgery

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

Study to Assess the Efficacy and Safety of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Heart, Using an Catheter Delivery System

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation

A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers

Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer